- ASSOCIATE PROFESSOR Medicine, Cardiology
Dr. Hulot serves as the Director of Pharnacogenomics and Personalized Therapeutics at the Cardiovascular Research Center. He is one of the co-investigators of the Institute of Personalized Medicine's innovative EMR-linked Biobank Program.
In the News: Dr. Jean-Sebastien Hulot discusses stent thrombosis in The Daily News feature The Daily Checkup.
Dr. Hulot is a co-Investigator of the NHGRI-funded U01 grant ‘Biorepositories for Genomic Medicine in Diverse Communities’. He has been involved in the conception and development of different clinical trials aiming to develop personalized medicine in cardiology (CLOVIS-2 NCT 00822666; GIANT trial NCT01134380; ARCTIC - Gene NCT 00827411). His laboratory is an affiliate member of the PharmacoGenetics Research Network. Dr Hulot has participated to the Clinical Pharmacogenetics Implementation Consortium (CPIC) working on clopidogrel pharmacogenetics and is a member of the steering committee of the National Institutes of Health (NIH) International Clopidogrel Pharmacogenetics Consortium (ICPC).
Dr. Hulot is also an NIH-funded investigator leading laboratory research on gene therapy in heart failure.
- Genetic basis of responses to cardiovascular drugs
- Human induced pluripotent stem cells in cardiovascular diseases
- Gene and genome-guided therapies in cardiovascular disease
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hulot did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Hess CSM Building Floor 7th Room s7-110
1470 Madison Avenue
New York, NY 10029